A citation-based method for searching scientific literature

Kenneth W Mahaffey, Meg J Jardine, Severine Bompoint, Christopher P Cannon, Bruce Neal, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull, George Capuano, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol Pollock, Tao Sun, David C Wheeler, Yshai Yavin, Hong Zhang, Bernard Zinman, Norman Rosenthal, Barry M Brenner, Vlado Perkovic. Circulation 2019
Times Cited: 101



David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl, Maximilian von Eynatten. Circulation 2014
Times Cited: 714




List of shared articles



Times cited

Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Jaime Blais, Qiang Li, Meg J Jardine,[...]. Am J Kidney Dis 2021
5

Recent advances in drug discovery for diabetic kidney disease.
Chhanda Charan Danta, Andrew N Boa, Sunil Bhandari, Thozhukat Sathyapalan, Shang-Zhong Xu. Expert Opin Drug Discov 2021
0

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl,[...]. Diabetes 2021
3

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl,[...]. Am J Kidney Dis 2021
11

Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
Husam M Salah, Subhi J Al'Aref, Muhammad Shahzeb Khan, Malek Al-Hawwas, Srikanth Vallurupalli, Jawahar L Mehta, J Paul Mounsey, Stephen J Greene, Darren K McGuire, Renato D Lopes,[...]. Am Heart J 2021
15


Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
Takayuki Yamada, Mako Wakabayashi, Abhinav Bhalla, Nitin Chopra, Hirotaka Miyashita, Takahisa Mikami, Hiroki Ueyama, Tomohiro Fujisaki, Yusuke Saigusa, Takahiro Yamaji,[...]. Cardiovasc Diabetol 2021
7


The impact of diabetes on heart failure development: The cardio-renal-metabolic connection.
Paul Valensi, Gaétan Prévost, Sara Pinto, Jean-Michel Halimi, Erwan Donal. Diabetes Res Clin Pract 2021
0

Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors.
William G Herrington, Gianluigi Savarese, Richard Haynes, Nikolaus Marx, Linda Mellbin, Lars H Lund, Paul Dendale, Petar Seferovic, Giuseppe Rosano, Natalie Staplin,[...]. Eur J Heart Fail 2021
1

Renoprotective effects of sodium-glucose cotransporter-2 inhibitors and underlying mechanisms.
Naoki Kashihara, Kengo Kidokoro, Eiichiro Kanda. Curr Opin Nephrol Hypertens 2020
7





Sodium-glucose co-transporter-2 inhibitors: peculiar "hybrid" diuretics that protect from target organ damage and cardiovascular events.
Riccardo Sarzani, Federico Giulietti, Chiara Di Pentima, Francesco Spannella. Nutr Metab Cardiovasc Dis 2020
3

Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial.
Megumi Oshima, Brendon L Neuen, JingWei Li, Vlado Perkovic, David M Charytan, Dick de Zeeuw, Robert Edwards, Tom Greene, Adeera Levin, Kenneth W Mahaffey,[...]. J Am Soc Nephrol 2020
12